Who is sponsoring NCT02553798?

NCT02553798 is sponsored by Journey Medical Corporation.

What condition does NCT02553798 study?

NCT02553798 studies Hyperhidrosis.

What drugs are being tested in NCT02553798?

Interventions: Glycopyrronium Topical Wipes.

What is the status of NCT02553798?

NCT02553798 is currently COMPLETED.

Last reviewed 2021-08-23 · How we verify

An Open-label Study Assessing Long-term Safety of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis

NCT02553798 Phase 3 COMPLETED Results posted

This is an open-label, long-term safety study of glycopyrronium topical wipes, enrolling up to 660 subjects with primary axillary hyperhidrosis who participated in either the DRM04-HH04 or DRM04-HH05 studies.

Details

Lead sponsor	Journey Medical Corporation
Phase	Phase 3
Status	COMPLETED
Enrolment	564
Start date	2015-08
Completion	2016-12

Conditions

Hyperhidrosis

Interventions

Glycopyrronium Topical Wipes

Primary outcomes

Long-term Safety Assessed Through Adverse Events and Local Skin Reactions — Day 1 - Week 44
The Total Participants at risk are based on the Safety population, defined as, Participants who were randomized and received at least one confirmed dose of study drug.

Countries

United States, Germany